ITUB20160650A1 - Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione - Google Patents

Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione

Info

Publication number
ITUB20160650A1
ITUB20160650A1 ITUB2016A000650A ITUB20160650A ITUB20160650A1 IT UB20160650 A1 ITUB20160650 A1 IT UB20160650A1 IT UB2016A000650 A ITUB2016A000650 A IT UB2016A000650A IT UB20160650 A ITUB20160650 A IT UB20160650A IT UB20160650 A1 ITUB20160650 A1 IT UB20160650A1
Authority
IT
Italy
Prior art keywords
trifluorometilbenzoil
cycloesandion
nitro
pharmaceutical formulations
solid stable
Prior art date
Application number
ITUB2016A000650A
Other languages
English (en)
Original Assignee
Dipharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dipharma S A filed Critical Dipharma S A
Priority to ITUB2016A000650A priority Critical patent/ITUB20160650A1/it
Priority to ES17703173T priority patent/ES2751746T3/es
Priority to AU2017216633A priority patent/AU2017216633A1/en
Priority to CN201780008088.3A priority patent/CN108495623B/zh
Priority to BR112018015483-0A priority patent/BR112018015483B1/pt
Priority to PCT/EP2017/052805 priority patent/WO2017137468A1/en
Priority to US15/766,665 priority patent/US10888527B2/en
Priority to RU2018124482A priority patent/RU2702746C1/ru
Priority to EP17703173.9A priority patent/EP3413876B1/en
Priority to JP2018540857A priority patent/JP6827474B2/ja
Publication of ITUB20160650A1 publication Critical patent/ITUB20160650A1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ITUB2016A000650A 2016-02-11 2016-02-11 Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione ITUB20160650A1 (it)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ITUB2016A000650A ITUB20160650A1 (it) 2016-02-11 2016-02-11 Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
ES17703173T ES2751746T3 (es) 2016-02-11 2017-02-09 Formulaciones farmacéuticas sólidas estables que contienen 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona
AU2017216633A AU2017216633A1 (en) 2016-02-11 2017-02-09 Stable solid pharmaceutical formulations containing 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
CN201780008088.3A CN108495623B (zh) 2016-02-11 2017-02-09 含有2-(2-硝基-4-三氟甲基-苯甲酰基)-1,3-环己二酮的稳定固体药物配制品
BR112018015483-0A BR112018015483B1 (pt) 2016-02-11 2017-02-09 Formulações farmacêuticas sólidas estáveis que contêm 2-(2-nitro-4-trifluorometil- benzoil)-1,3 -ciclo-hexanodiona
PCT/EP2017/052805 WO2017137468A1 (en) 2016-02-11 2017-02-09 Stable solid pharmaceutical formulations containing 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
US15/766,665 US10888527B2 (en) 2016-02-11 2017-02-09 Stable solid pharmaceutical formulations containing 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cylcohexanedione
RU2018124482A RU2702746C1 (ru) 2016-02-11 2017-02-09 Стабильные твёрдые фармацевтические составы, содержащие 2-(2-нитро-4-трифторметилбензоил)-1,3-циклогександион
EP17703173.9A EP3413876B1 (en) 2016-02-11 2017-02-09 Stable solid pharmaceutical formulations containing 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
JP2018540857A JP6827474B2 (ja) 2016-02-11 2017-02-09 2−(2−ニトロ−4−トリフルオロメチルベンゾイル)−1,3−シクロヘキサンジオンを含有する安定な固形医薬製剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2016A000650A ITUB20160650A1 (it) 2016-02-11 2016-02-11 Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione

Publications (1)

Publication Number Publication Date
ITUB20160650A1 true ITUB20160650A1 (it) 2017-08-11

Family

ID=55969291

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUB2016A000650A ITUB20160650A1 (it) 2016-02-11 2016-02-11 Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione

Country Status (10)

Country Link
US (1) US10888527B2 (it)
EP (1) EP3413876B1 (it)
JP (1) JP6827474B2 (it)
CN (1) CN108495623B (it)
AU (1) AU2017216633A1 (it)
BR (1) BR112018015483B1 (it)
ES (1) ES2751746T3 (it)
IT (1) ITUB20160650A1 (it)
RU (1) RU2702746C1 (it)
WO (1) WO2017137468A1 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9783485B1 (en) 2016-11-30 2017-10-10 Dipharma S.A. Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof
CN112107548A (zh) * 2020-10-30 2020-12-22 兆科药业(广州)有限公司 一种含有尼替西农的药物组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181292A1 (en) * 2012-05-29 2013-12-05 Biotie Therapies, Inc. Nitisinone formulations
WO2015101794A1 (en) * 2014-01-03 2015-07-09 Cycle Pharmaceuticals Ltd Pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69228813T2 (de) * 1991-06-24 1999-08-05 Zeneca Ltd., London Verwendung von 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen
GB9501433D0 (en) 1995-01-25 1995-03-15 Zeneca Ltd Chemical process
GB0504103D0 (en) 2005-02-28 2005-04-06 Syngenta Ltd Novel method
RU2384330C2 (ru) * 2007-12-18 2010-03-20 Закрытое Акционерное Общество "Канонфарма Продакшн" Композиция 3-окси-6-метил-2-этилпиридина или его фармацевтически приемлемой соли, выполненная в форме таблетки, способ ее получения и способ лечения
CA2742841A1 (en) * 2008-11-06 2010-05-14 Biotie Therapies, Inc. Treatment of restless leg syndrome and sleep disorders
US8354451B2 (en) 2009-03-09 2013-01-15 The Uwm Research Foundation, Inc. Treatment of microbial infections with compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase
WO2011106655A1 (en) 2010-02-26 2011-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation
RU2605301C2 (ru) 2011-06-23 2016-12-20 Сведиш Орфан Биовитрум Интернэшнл Аб Жидкая фармацевтическая композиция, включающая нитизинон
CA2851433A1 (en) * 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-methyl-propargyl-aminoindan
UA117141C2 (uk) * 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181292A1 (en) * 2012-05-29 2013-12-05 Biotie Therapies, Inc. Nitisinone formulations
WO2015101794A1 (en) * 2014-01-03 2015-07-09 Cycle Pharmaceuticals Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
CN108495623A (zh) 2018-09-04
CN108495623B (zh) 2021-04-20
RU2702746C1 (ru) 2019-10-11
WO2017137468A1 (en) 2017-08-17
JP6827474B2 (ja) 2021-02-10
EP3413876B1 (en) 2019-09-18
BR112018015483B1 (pt) 2021-02-02
JP2019504846A (ja) 2019-02-21
BR112018015483A2 (pt) 2018-12-18
US20190160014A1 (en) 2019-05-30
US10888527B2 (en) 2021-01-12
AU2017216633A1 (en) 2018-07-26
ES2751746T3 (es) 2020-04-01
EP3413876A1 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
EP4008319C0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MELOXICAM
EP3621621C0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MELOXICAM
EP3493799A4 (en) Cannabis
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
SI3529248T1 (sl) Farmacevtske spojine
MA50541A (fr) Formulations pharmaceutiques
BR112016023628A2 (pt) composições farmacêuticas.
DK3518892T3 (da) Farmaceutisk formulering, der indeholder en insulinforbindelse
MA46867A (fr) Formulations pharmaceutiques
EP3454899C0 (en) PHARMACEUTICAL COMPOSITION
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
MA42303A (fr) Formulations pharmaceutiques
DK3529240T3 (da) Farmaceutiske forbindelser
HUE049437T2 (hu) Hatóanyagként heterociklusos diamino-karboxamid vegyületet tartalmazó gyógyászati készítmény
DK3278801T3 (da) Farmaceutisk sammensætning indeholdende mirabegron
EP3454847A4 (en) IMPROVED DRUG FORMULATIONS
EP3402470A4 (en) STABLE PHARMACEUTICAL COMPOSITION
LT3389633T (lt) Farmacinės kompozicijos, apimančios fenilaminopirimidino darinį
PL4023651T3 (pl) Aktywna optycznie pochodna piranochromenylofenolu i kompozycja farmaceutyczna ją zawierająca
EP3337463A4 (en) PHARMACEUTICAL FORMULATIONS
DK3280447T3 (da) Farmaceutiske formuleringer
IL248012A0 (en) Porous materials containing compounds including pharmaceutically active species
DK3453390T3 (da) Farmaceutisk sammensætning indeholdende polymeriseret lægemiddel
ITUB20160650A1 (it) Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
EP3831373A4 (en) SOLID DRUG FORMULATION CONTAINING A STABILIZER